Richard took up his role as Director General in August 2004 and, during his tenure, has successfully led the organisation through an evolution to establish the ABPI as one of the most effective national associations in its sector worldwide. The ABPI has built strong links to government and the health service, robust representation in shaping the UK marketplace and delivered a series of initiatives to advance the reputation and impact of the industry.
Richard Barker said, “My time at the ABPI has been both challenging and fulfilling and I have been proud to represent this vital industry. It is both an engine of growth to support economic recovery and a continuing source of new medicines and vaccines to help the NHS deliver improved health. With the UK environment going through further rapid and dynamic evolution, next year will be a good time to hand over the reins to a new leader. I look forward to pursuing new opportunities outside the Association in the future, principally in healthcare. In the meantime, I am very much focused on continuing the vital work we are doing at the ABPI.”
The search for Richard’s successor will begin immediately, with the aim of making an appointment in Spring 2011. This will allow Richard’s successor to work with Simon Jose, the current President of the ABPI, for a full year before the next change in President.
Following a handover to his successor in May 2011, Richard will act as a senior advisor to the Association for a period of up to 12 months. Until the handover, it will be ‘business as usual’ and Richard will continue to drive progress on major programmes of work, in particular to ensure the industry engages effectively with its members and other key stakeholders as the healthcare environment goes through a rapid evolution, and to complete a relocation of the Association to new London offices.
Simon Jose, President of the ABPI, said “Richard has been a very visible champion for the ABPI over the past six years, engaging in both private and public discussions about a wide range of issues – from the importance of retaining clinical research in the UK, to mitigating the risk of medicines supply shortages – which are key not only to the industry, but to patients and the NHS. Under his leadership, the industry has worked increasingly closely and constructively with the UK Government and he played a leading role in establishing the Office for Life Sciences, and from it the launch of the UK’s Life Sciences Supercluster and personalised medicine initiatives.
“Richard has also led the ABPI through an important evolution internally, which has established some firm foundations that his successor will be able to build on as we look to take the ABPI forward into a new era.”
For further information, please contact the ABPI press office: 020 7747 1410.